One polio shot enough? new trial tests simpler vaccine schedule

NCT ID NCT07354269

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sinovac Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 4 study compares a single dose of an inactivated polio vaccine (sIPV) in people aged 7 to 50 years with the standard three-dose series given to infants. Researchers want to see if one shot can produce a similar immune response. The trial is recruiting 180 healthy participants and will monitor safety and antibody levels 30 days after vaccination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Inactivated polio vaccine (sIPV) and DTaP-IPV-Hib pentavalent vaccine
What this could lead to: If successful, this could show that a single polio vaccine dose works as well in older children and adults as the three-dose series given to infants, simplifying booster campaigns.
What could go wrong: This is a small, early-phase study comparing different age groups, not a direct test of disease prevention. Results may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLIOMYELITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

poliomyelitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLIOMYELITIS

Contacts and locations

Locations

Chengguan District Center for Disease Prevention and Control, Lanzhou City
RECRUITING

Lanzhou, Gansu, China
Longxi County Center for Disease Prevention and Control, Dingxi City
RECRUITING

Dingxi, Gansu, China
Zhangye Center for Disease Prevention and Control
RECRUITING

Zhangye, Gansu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.